New hope for frail hodgkin patients: immunotherapy-chemo combo shows promise
NCT ID NCT07275216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding pembrolizumab (an immunotherapy) to a gentler chemotherapy mix can safely treat frail patients newly diagnosed with classical Hodgkin lymphoma who cannot handle standard strong chemo. About 23 participants will receive the combination and be monitored for cancer shrinkage. The goal is to find an effective, less toxic option for this vulnerable group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune booster before chemo may shrink hodgkin tumors with fewer drugs
- Immune booster may strengthen stem cell transplant against hodgkin lymphoma
- Two-Drug combo aims to outsmart resistant hodgkin lymphoma
- Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
- Can an old drug make immunotherapy work again for hodgkin lymphoma?
- New immunotherapy combo aims to boost hodgkin lymphoma remission